Pulmonary Engraftment Syndrome: A unique complication of allogeneic hematopoietic cell transplantation for myelofibrosis

Pulmonary Engraftment Syndrome: A unique complication of allogeneic hematopoietic cell transplantation for myelofibrosis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Pulmonary Engraftment Syndrome: A unique complication of allogeneic hematopoietic cell transplantation for myelofibrosis Vinod Pullarkat, Salman Otoukesh, Idoroenyi Amanam, Dongyun Yang, and 15 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3970614/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Allogeneic hematopoietic cell transplantation (alloHCT) is the only potentially curative modality for primary and secondary myelofibrosis (MF) due to other myeloproliferative neoplasms. However, alloHCT in MF is complicated by cardiopulmonary comorbidities that frequently exist in these patients, which in turn translates into higher non relapse mortality (NRM). We describe a syndrome of pulmonary infiltration and respiratory compromise (pulmonary engraftment syndrome, PES) that occurred at time of engraftment in patients undergoing alloHCT for MF. Eighteen of 83 (22%) patients experienced PES as defined and radiologic findings included ground glass opacities, consolidation or pulmonary nodularity. Only a third of patients had other features of engraftment syndrome. Pulmonary arterial hypertension was associated with occurrence of PES (Odds ratio 3.68 [95% CI 1.13,12; P = 0.04]). There was no association of PES with pre HCT pulmonary function testing or imaging. Hypoxemia occurred in 15 of 18 patients. Although 44% of the 18 patients who developed PES required intensive care and 40% required mechanical ventilation, all patients responded to supportive management and treatment with corticosteroids. Occurrence of PES did not adversely impact overall survival or NRM. PES is a distinct syndrome that occurs after alloHCT for MF and is associated with significant morbidity making its early recognition important. Biological sciences/Cancer/Haematological cancer/Myeloproliferative disease Biological sciences/Cancer/Cancer therapy/Cancer immunotherapy Figures Figure 1 Figure 2 Introduction Allogeneic hematopoietic cell transplantation (alloHCT) is the only potentially curative modality for primary and secondary myelofibrosis due to other myeloproliferative neoplasms (MPN).[ 1 ] Although alloHCT is associated with favorable long-term outcomes, there is high non-relapse mortality (NRM) post-transplant which could be as high as 35%.[ 2 ] This relatively high NRM is likely contributed by advanced age, comorbid conditions, and organ dysfunction that frequently exists in these patients [ 3 ]. Engraftment syndrome (ES) is a clinical syndrome that includes fever, skin rash, pulmonary infiltration, weight gain, liver and/or renal dysfunction, and/or rarely encephalopathy, which usually occurs at the time of neutrophil engraftment and carries the potential risk of multi-organ failure and/or death.[ 4 – 6 ] Although criteria for diagnosis of ES have been proposed, ES remains a diagnosis of exclusion, and its reported incidence varies widely. Since there are no standard diagnostic criteria for ES, this entity has a wide range of incidence (7–90%) in literature. [ 7 ] ES may have an adverse impact on HCT outcome. In a study of 927 pediatric patients who underwent alloHCT, Chang et al reported a significantly higher incidence of grade 2–4 acute GVHD (75% vs. 34%), 2-year non-relapse mortality (38% vs. 19%), and lower overall survival (2-yr OS) (38% vs. 54%) compared with the non-ES group (P < 0.001). [ 8 ] Differences in patient populations, HCT characteristics, and the nature of the disease may influence the incidence of ES. The pathophysiology of ES is not well understood, but inflammatory cytokines are implicated, leading to capillary leak, constitutional symptoms, and organ failure.[ 4 , 7 ] In myelofibrosis patients undergoing alloHCT, we have observed a variant of engraftment syndrome manifesting as pulmonary infiltrates with or without hypoxemia which we termed pulmonary engraftment syndrome (PES). This presentation could be related to pulmonary extramedullary hematopoiesis that has been described in MF patients [ 9 , 10 ]. Therefore, we sought to characterize this unique syndrome further and determine its association with pre-HCT patient and disease characteristics and determine its impact on HCT outcome. We previously published our experience with pulmonary arterial hypertension (PAH) in myelofibrosis which was associated with adverse HCT outcomes [ 11 ]. Therefore we also sought to determine if an association exists between PES and pre-HCT pulmonary tests, particularly PAH. Methods Patients This study was approved by the Institutional Review Board of City of Hope Medical Center. From our HCT database, we identified 83 patients with primary/secondary myelofibrosis who underwent alloHCT at our institution from 2015 to 2020. Data on patient demographics, disease characteristics, disease status at HCT, mutations, HCT-related variables and outcome measures were collected from patient medical records. Definition of pulmonary engraftment syndrome We defined pulmonary ES was defined as the combination of new onset of pulmonary opacities in the absence of infection, fluid overload, or left ventricular dysfunction with or without hypoxemia occurring between ten to twenty days after stem cell infusion. All patients were required to have neutrophil engraftment after stem cell infusion. Other characteristics for engraftment syndrome were noted which included: noninfectious fever, erythematous rash not attributed to GvHD, liver dysfunction, acute kidney injury and encephalopathy. Statistical analysis Descriptive statistics were used for patient baseline demographic, disease, and transplant characteristics. The associations between baseline characteristics and pulmonary ES were assessed by Fisher’s exact test in the univariate analysis, and exact logistic regression models in the multivariable model. The HCT outcomes by pulmonary ES were evaluated by Kaplan-Meier curves and log-rank tests for OS, by cumulative incidence curves and Gray’s test for NRM and engraftments. All tests were 2-sided at 0.05 significance level. Results Patient demographics and baseline characteristics Among the 83 patients included in this study, 49% had PMF, and 51% had MF secondary to another MPN. Their median age was 62 years (range 55–68) and the majority of the patients were male (n = 53,64%). The JAK2 V617F mutation was detected in 65% (n = 54) of patients. Prior to an alloHCT, 61% (n = 51) had received treatment with ruxolitinib. The median spleen size was 20 cm (range 16–23 cm). > 90% of patients had ≥ MF2 bone marrow fibrosis. Patient characteristics are shown in detail in Table 1 . Hematopoietic Cell Transplantation . The median HCT CI score was 2 (range 0–7). Graft source for alloHCT was matched unrelated donor (MUD) in 54%, followed by matched related donor (MRD) in 23%, mis-matched unrelated (MMUD) in 12%, and haplo-identical donor in 11%. Mobilized peripheral blood stem cells were used as a graft source in 97.6% of donors. Fludarabine-melphalan was the most common conditioning regimen used (83%). Tacrolimus/sirolimus GVHD prophylaxis was used in more than half of the patients (57.8%, n = 48). The median CD34 + and CD3 cells were infused at a median 6x10 6 cells/kg (range: 2.49–12.96) and 2.21x10 6 cells/kg (range: 0.25–4.90) respectively. The median time for neutrophil engraftment was 20.0 days. The median time for platelet engraftment was 37.0 days. Details of HCT are depicted in Table 1 . Table 1. Patient and HCT characteristics Total (N = 83) Age at HCT, years Median 62 Interquartile range 55, 68 Range (17–75) Recipient sex Male 53 (63.9%) Female 30 (36.1%) Karnofsky performance status % Missing 3 (3.6%) 70 6 (7.2%) 80 31 (37.3%) 90 35 (42.2%) 100 8 (9.6%) 80–100 74 (89.2%) <80 6 (7.2%) Unknown 3 (3.6%) HCT Comorbidity Index Median 2 Interquartile range 0, 3 Range (0–7) 0 21 (25.3%) 1–2 24 (28.9%) ≥ 34 (41%) Unknown 4 (4.8%) Primary MF Yes 41 (49.4%) No 42 (50.6%) JAK2 mutation Yes 54 (65.1%) No 29 (34.9%) Degree of marrow fibrosis Missing 2 (2.4%) 1+ 6 (7.2%) 2+ 33 (39.8%) 3+ 42 (50.6%) Ruxolitinib therapy Yes 50 (60.2%) No 33 (39.8%) Pre HCT EF N 81 Median 61 Interquartile range 60, 65 Range (45–69) Pre HCT PASP (mmhg) N 79 Median 28 Interquartile range 20, 34 Range (3–74) Pre HCT Spleen Size (cm) N 75 Median 20 Interquartile range 16, 23 Range (10–34) Year of HCT 2015 17 (20.5%) 2016 12 (14.5%) 2017 14 (16.9%) 2018 15 (18.1%) 2019 21 (25.3%) 2020 4 (4.8%) Donor Type MRD 19 (22.9%) MUD 45 (54.2%) MMUD 10 (12%) Haplo 9 (10.8%) Donor sex Male 60 (72.3%) Female 23 (27.7%) Female donor to male recipient Yes 13 (15.7%) No 70 (84.3%) Donor age Median 36 Interquartile range 27, 47 Range (18–69) Graft Source Bone Marrow 2 (2.4%) Peripheral Blood Stem Cells 81 (97.6%) ABO blood group compatibility ABO compatible 48 (57.8%) Minor mismatch (donor is O) 13 (15.7%) Major mismatch (Recipient is O) 15 (18.1%) Bidirectional (None are O) 7 (8.4%) Donor/Recipient CMV serostatus D-/R- 14 (16.9%) D-/R+ 29 (34.9%) D+/R- 8 (9.6%) D+/R+ 32 (38.6%) Conditioning regimen BUSULFAN/CTX 4 (4.8%) FLUDARABINE/BUSULFAN 1 (1.2%) FLUDARABINE/CTX/TBI 1 (1.2%) FLUDARABINE/MELPHALAN 67 (80.7%) FLUDARABINE/MELPHALAN/Ruxolitinib/ 2 (2.4%) FLUDARABINE/MELPHALAN/TBI 7 (8.4%) FTBI/FLUDARABINE 1 (1.2%) Conditioning Regimen Intensity Myeloblative 5 (6%) Non-myeloablative/Reduced Intensity 78 (94%) GVHD prophylaxis CTX/TACROLIMUS/CELLCEPT 14 (16.9%) TACROLIMUS/MTX 5 (6%) TACROLIMUS/MTX/BORTEZOMIB 1 (1.2%) TACROLIMUS/SIROLIMUS 48 (57.8%) TACROLIMUS/SIROLIMUS/MTX 3 (3.6%) TACROLIMUS/SIROLIMUS/OTHER 1 (1.2%) TACROLIMUS/SIROLIMUS/Ruxolitinib 11 (13.3%) Pulmonary Engraftment Syndrome Twenty-five patients (30%) had pulmonary infiltrates between days 10 and 20 of HCT. Radiologic findings included ground glass opacities, areas of consolidation or pulmonary nodules. Among them, eighteen patients (72%) met the criteria for pulmonary ES. Eight patients (44%) required an ICU admission. Fifteen (83%) patients had hypoxemia that required supplemental oxygen, and six (40%) of these patients required intubation with mechanical ventilation. Of the remaining patients with hypoxemia, two patients (13%) required high flow oxygen and seven (47%) required 2-6L of oxygen via nasal cannula. The most common engraftment symptoms included fever (33%), diarrhea (33%), and rash (22%). Half (n = 9) of the patients with PES required systemic steroid therapy. Risk factors for pulmonary engraftment syndrome The association of pre-HCT pulmonary parameters with PES is shown in Table 2 . Demographic factors and transplant characteristics did not reveal any risk factors for PES (Table 3 ). Pre-HCT CT scan chest was reported as normal in 87% of patients. Among the 18 patients who experienced PES, 9 had nodules (≤ 5mm) on pre HCT CT imaging. Representative CT images for 2 patients with PES are shown in Fig. 1 . Table 2 Association of disease and HCT factors with occurrence of PES PES N Yes No Fisher's exact test p value Adjusted OR (95%CI)* P value* Age at HCT (years) < 65 44 9(20.5%) 35(79.5%) 0.80 Reference 1.00 ≥ 65 39 9(23.1%) 30(76.9%) 0.88(0.24,3.05) Sex M 53 11(20.8%) 42(79.2%) 0.79 Reference 1.00 F 30 7(23.3%) 23(76.7%) 1.07(0.29,3.74) KPS, % 90–100 43 10(23.3%) 33(76.7%) 0.79 Reference 1.00 ≤ 80 37 7(18.9%) 30(81.1%) 0.86(0.23,3.04) HCT Comorbidity Index 0 21 4(19.0%) 17(81.0%) 0.62 Reference 0.74 1–2 25 7(28.0%) 18(72.0%) 1.67(0.28,11.02) ≥ 3 34 6(17.6%) 28(82.4%) 0.98(0.19,5.71) Donor Matched 64 13(20.3%) 51(79.7%) 0.54 Reference 0.74 MMUD or Haplo 19 5(26.3%) 14(73.7%) 1.28(0.28,5.23) Female to Male HCT No 70 16(22.9%) 54(77.1%) 0.72 Reference 0.71 Yes 13 2(15.4%) 11(84.6%) 0.53(0.05,3.00) Primary MF Yes 41 8(19.5%) 33(80.5%) 0.79 Reference 0.79 No 42 10(23.8%) 32(76.2%) 1.18(0.34,4.17) JAK2 mutation Yes 54 14(25.9%) 40(74.1%) 0.27 Reference 0.16 No 29 4(13.8%) 25(86.2%) 0.39(0.08,1.50) Degree of fibrosis (MF grade) 1 + or 2+ 39 9(23.1%) 30(76.9%) 1.00 Reference 1.00 3+ 42 9(21.4%) 33(78.6%) 0.88(0.24,3.24) Ruxolitinib use Yes 50 14(28.0%) 36(72.0%) 0.11 Reference 0.099 No 33 4(12.1%) 29(87.9%) 0.35(0.07,1.34) Pre HCT EF ≤ 60 40 11(27.5%) 29(72.5%) 0.30 Reference 0.77 > 60 41 7(17.1%) 34(82.9%) 0.74(0.20,2.70) Pre BMT PASP (mmHg) ≤ 28 43 4(9.3%) 39(90.7%) 0.011 Reference 0.011 > 28 36 12(33.3%) 24(66.7%) 4.78(1.26,22.69) < 35 61 9(14.8%) 52(85.2%) 0.042 Reference 0.042 ≥ 35 18 7(38.9%) 11(61.1%) 3.68(1.13,12.00) Pre HCT Spleen Size (cm) < 20 39 6(15.4%) 33(84.6%) 0.26 Reference 0.23 ≥ 20 36 10(27.8%) 26(72.2%) 2.21(0.54,9.82) Pre HCT CT chest finding Normal 72 17(23.6%) 55(76.4%) 0.44 Reference 0.42 Abnormal 11 1(9.1%) 10(90.9%) 0.29(0.01,2.52) Pre HCT FEV1 ≥ 80% 63 11(17.5%) 52(82.5%) 0.28 Reference 0.25 < 80% 15 5(33.3%) 10(66.7%) 2.60(0.50,13.32) Pre HCT FEV1/FVC ≥ 70% 60 13(21.7%) 47(78.3%) 0.75 Reference 1.00 < 70% 18 3(16.7%) 15(83.3%) 0.84(0.08,5.40) Pre HCT DLCO ≥ 80% 21 5(23.8%) 16(76.2%) 0.76 Reference 0.74 < 80% 56 11(19.6%) 45(80.4%) 0.79(0.18,4.10) * Based on exact logistic regression adjusting for Pre HCT pulmonary pressure Table 3 Association of patient and HCT characteristics with OS and NRM Overall Survival NRM N 1 Yr (95%CI)* HR (95%CI)* P* Adjusted HR (95%CI)† P† 100 day (95%CI)* HR (95%CI)* P* Adjusted HR (95%CI) † P† Age at HCT, years < 65 44 0.656(0.494,0.776) Reference 0.82 Reference 0.56 0.114(0.041,0.227) Reference 0.71 Reference 0.67 ≥ 65 39 0.615(0.445,0.747) 1.08(0.55,2.11) 1.22(0.62,2.40) 0.205(0.095,0.344) 1.13(0.51,2.51) 1.19(0.53,2.66) Sex M 53 0.657(0.512,0.769) Reference 0.65 Reference 0.64 0.132(0.057,0.238) Reference 0.81 Reference 0.84 F 30 0.600(0.405,0.750) 1.16(0.59,2.29) 1.18(0.58,2.41) 0.200(0.079,0.360) 1.16(0.51,2.61) 1.09(0.47,2.51) KPS, % 90–100 43 0.647(0.484,0.771) Reference 0.90 Reference 0.83 0.186(0.086,0.315) Reference 0.31 Reference 0.25 ≤ 80 37 0.649(0.473,0.779) 0.96(0.48,1.90) 0.93(0.47,1.85) 0.108(0.034,0.233) 0.63(0.27,1.48) 0.60(0.25,1.44) HCT Comorbidity Index 0 21 0.571(0.338,0.749) Reference 0.15 Reference 0.81 0.238(0.083,0.437) Reference 0.53 Reference 0.67 1–2 25 0.513(0.304,0.689) 0.89(0.40,2.01) 1.13(0.46,2.79) 0.120(0.029,0.280) 0.67(0.25,1.79) 0.72(0.26,1.99) ≥ 3 34 0.765(0.584,0.875) 0.48(0.21,1.13) 0.84(0.33,2.11) 0.147(0.053,0.287) 0.60(0.23,1.56) 0.65(0.25,1.71) Donor Matched 64 0.686(0.556,0.784) Reference 0.065 Reference 0.022 0.125(0.058,0.219) Reference 0.25 Reference 0.27 MMUD or Haplo 19 0.474(0.244,0.673) 1.92(0.94,3.93) 2.41(1.13,5.11) 0.263(0.092,0.474) 1.66(0.68,4.05) 1.66(0.68,4.05) Female to Male HCT No 70 0.627(0.503,0.729) Reference 0.94 Reference 0.81 0.157(0.083,0.252) Reference 0.77 Reference 0.82 Yes 13 0.692(0.373,0.872) 0.96(0.37,2.48) 1.12(0.43,2.92) 0.154(0.022,0.399) 1.15(0.41,3.27) 1.13(0.40,3.20) Primary MF Yes 41 0.707(0.543,0.822) Reference 0.34 Reference 0.75 0.171(0.074,0.301) Reference 0.51 Reference 0.44 No 42 0.568(0.405,0.702) 1.37(0.70,2.67) 1.12(0.56,2.23) 0.143(0.057,0.266) 1.34(0.60,2.99) 1.38(0.61,3.10) JAK2 mutation Yes 54 0.630(0.487,0.743) Reference 0.99 Reference 0.66 0.167(0.081,0.278) Reference 0.52 Reference 0.57 No 29 0.651(0.448,0.795) 1.00(0.50,1.98) 1.18(0.56,2.50) 0.138(0.042,0.289) 0.78(0.34,1.78) 0.79(0.34,1.81) Degree of marrow fibrosis 1 + or 2+ 39 0.615(0.445,0.747) Reference 0.34 Reference 0.30 0.205(0.095,0.344) Reference 0.35 Reference 0.45 3+ 42 0.687(0.522,0.805) 0.72(0.36,1.43) 0.68(0.33,1.41) 0.119(0.043,0.237) 0.65(0.28,1.52) 0.71(0.29,1.72) Ruxolitinib therapy Yes 50 0.640(0.491,0.756) Reference 0.78 Reference 0.46 0.160(0.074,0.275) Reference 0.68 Reference 0.64 No 33 0.632(0.442,0.772) 1.10(0.56,2.14) 1.32(0.63,2.77) 0.152(0.054,0.295) 1.21(0.55,2.66) 1.21(0.55,2.67) Pre HCT EF ≤ 60 40 0.721(0.553,0.835) Reference 0.87 Reference 0.65 0.125(0.045,0.248) Reference 0.50 Reference 0.55 > 60 41 0.585(0.420,0.718) 1.06(0.53,2.09) 0.84(0.41,1.74) 0.195(0.090,0.329) 1.32(0.57,3.05) 1.30(0.56,2.99) Pre HCT PASP(mmHg) ≤ 28 43 0.674(0.513,0.793) Reference 0.46 Reference 0.10 0.140(0.056,0.261) Reference 0.81 Reference 0.83 > 28 36 0.636(0.457,0.770) 1.28(0.64,2.57) 1.88(0.88,4.00) 0.194(0.084,0.338) 1.14(0.50,2.61) 1.09(0.48,2.47) < 35 61 0.719(0.587,0.815) Reference 0.007 Reference < 0.001 0.115(0.050,0.209) Reference 0.031 Reference 0.040 ≥ 35 18 0.444(0.216,0.651) 2.58(1.24,5.40) 4.68(1.93,11.37) 0.333(0.131,0.552) 2.55(1.07,6.08) 2.42(1.04,5.62) Pre HCT Spleen Size (cm) < 20 39 0.872(0.719,0.945) Reference < 0.001 Reference < 0.001 0.103(0.032,0.222) Reference 0.083 Reference 0.094 ≥ 20 36 0.444(0.280,0.596) 3.70(1.67,8.22) 4.14(1.83,9.36) 0.194(0.084,0.338) 2.18(0.88,5.39) 2.17(0.88,5.38) Pre HCT CT chest finding Normal 72 0.651(0.528,0.749) Reference 0.42 Reference 0.19 0.139(0.071,0.229) Reference 0.47 Reference 0.60 Abnormal 11 0.545(0.229,0.780) 1.42(0.59,3.44) 1.84(0.75,4.55) 0.273(0.058,0.552) 1.47(0.50,4.33) 1.36(0.44,4.22) Pre HCT FEV1 ≥ 80% 63 0.635(0.504,0.740) Reference 0.66 Reference 0.96 0.175(0.093,0.278) Reference 0.17 Reference 0.21 < 80% 15 0.660(0.365,0.843) 0.82(0.34,1.99) 1.03(0.41,2.54) 0.067(0.004,0.270) 0.38(0.09,1.60) 0.39(0.09,1.68) Pre HCT FEV1/FVC ≥ 70% 60 0.631(0.496,0.740) Reference 0.45 Reference 0.80 0.150(0.073,0.252) Reference 0.67 Reference 0.97 < 70% 18 0.667(0.404,0.834) 0.72(0.30,1.73) 0.88(0.35,2.27) 0.167(0.039,0.372) 0.78(0.26,2.29) 0.98(0.32,3.03) Pre HCT DLCO ≥ 80% 21 0.714(0.472,0.860) Reference 0.24 Reference 0.064 0.048(0.003,0.202) Reference 0.37 Reference 0.39 < 80% 56 0.624(0.484,0.736) 1.68(0.69,4.08) 2.36(0.95,5.87) 0.196(0.104,0.310) 1.66(0.58,4.73) 1.59(0.55,4.58) PES No 65 0.677(0.549,0.776) Reference 0.062 Reference 0.074 0.138(0.068,0.234) Reference 0.26 Reference 0.26 Yes 18 0.500(0.259,0.701) 1.94(0.95,3.96) 1.93(0.94,3.97) 0.222(0.065,0.436) 1.65(0.70,3.89) 1.63(0.70,3.83) * based on univariate analysis, log-rank test for OS, and Gray’s test for NRM † Based on multivariable Cox regression model for OS adjusting for donor type and pre BMT spleen size, and Fine and Gray regression model for NRM adjusting for donor type. Pulmonary hypertension is a well-recognized complication of MF. Pulmonary artery systolic pressure measurement was available in 79 patients. In this cohort, the median pulmonary artery systolic pressure (PASP) for the cohort was 28 mmHg (range 3–74 mm Hg). Pulmonary artery hypertension (defined as PASP ≥ 35 mmHg) was observed in 61 patients (77%) in this cohort. PAH was associated with increased risk of PES with an odds ratio 3.68 (95% CI 1.13,12; P = 0.04) An abnormal pulmonary function test (PFT), defined as FEV1 < 80%, FEV1/FVC < 70%, and DLCO < 80 were found in 19%, 23% and 72% patients during pre-HCT testing, respectively. No association was seen between PFT abnormalities prior to transplant and the occurrence of PES was observed. (FEV1 p = 0.25 [95% CI 2.60 0.50-13.32], FEV1/FVC p = 1.00, [95% CI 0.84 0.08–5.40], DLCO p = 0.74 [95% CI 0.18–4.10]). Spleen size was not associated with the occurrence of PES (p = 0.23, 95% CI 2.21 0.54–9.82). Neutrophil engraftment was noted to be earlier in those with PES (median 17 days vs 20 days) but this was not statistically significant (p = 0.20). Overall Survival (OS) and Non-Relapse Mortality (NRM) The 12-month OS and 2-yr OS were 65% and 63%, respectively. The day 100 mortality was 16% and 2-year NRM was 24%. ( Fig. 2 ) Patients who experienced PES had no difference in overall survival (OS) and non-relapse mortality (NRM) in comparison to those who did not have PES (HR;1.93, 95% CI 0.94–3.97, P 0.074 and HR 1.63; 95% CI 0.70–3.83, P 0.26, respectively). Median ICU stay for patients with PES was 18 days. Patients with median PASP > 35 and pre-HCT spleen size > 20 cm had worse OS in multivariate analysis (HR 2.58, 95% CI 1.24–5.40, P < 0.001, and HR 4.14, 95% CI 1.83–9.36, p < 0.001), while pre-HCT median PASP of greater or equal with 35 mmHg was associate with worse NRM (HR 2.42, 95% CI 1.04–5.62, p 0.040) Patient, donor, and transplant characteristics and their association with OS and NRM are listed in Table 3 . Discussion In this study, we describe a novel variant of engraftment syndrome consisting of predominantly pulmonary infiltrates, occurring around the time of neutrophil engraftment in patients undergoing alloHCT for MF. Only a third of these patients had extrapulmonary features of engraftment syndrome. Although this syndrome was not associated with decreased OS or increased NRM, it was associated with significant morbidity and requires early recognition to initiate corticosteroid therapy which appears to be effective. Although the precise mechanism of PES remains unclear, it appears related to pulmonary extramedullary hematopoiesis (EMH) and PAH which are unique comorbidities in MF patients undergoing HCT. Cardiopulmonary morbidity frequently coexists in patients with myelofibrosis and PAH is a frequent occurrence in these patients. We have previously shown that PAH is common in MF patients and contributes to morbidity and mortality after alloHCT in MF [ 11 ]. In that study PAH was present in up to 50% of the cases prior to transplant and was associated with inferior overall survival (OS) (58.9% vs. 88.8%, P = 0.025) and increased NRM (21.6% vs. 7.1%, P = 0.007).[ 11 ] In this cohort of patients, we further confirm the association of PAH with adverse HCT outcome and show an association of PES with PAH prior to HCT. Other contributing factors to cardiopulmonary comorbidity in MF may include the hemodynamic changes related to splenomegaly and portal hypertension as well as chronic thromboembolic phenomena. Various reports have documented pulmonary EMH in patients with myelofibrosis, both primary and secondary to another MPN. This has been demonstrated in both biopsy specimens as well as non-invasively using technetium sulfur colloid scintigraphy [ 9 , 10 , 12 ]. Pulmonary EMH has also been implicated in pathogenesis of PAH in MF and involvement of pulmonary arteries by EMH as well as arteriopathy has been demonstrated in biopsy specimens [ 9 , 12 , 13 ]. The contribution of pulmonary EMH to PAH may explain the association of PES with PAH that we observed in this study. It can be hypothesized that engraftment of donor cells in foci of pulmonary EMH may underlie the pathogenesis of PES. Routine chest CT imaging appears insensitive to demonstrate pulmonary EMH unless it is symptomatic. In our cohort of 18 patients who experienced PES only half had small nodules (less than 1 cm) detected on pre HCT chest CT imaging. Given the prognostic significance of pulmonary EMH to HCT outcome it may be useful to perform specialized imaging by magnetic resonance imaging, Indium 111 or sulfur colloid scintigraphy to determine extent of pulmonary EMH and assess pre HCT risk in patients with MF, particularly those with abnormal pre HCT chest imaging or PAH. A variety of radiologic findings have been observed in patients with pulmonary EMH. These include ground glass opacities, areas of consolidation, pulmonary nodules as well as pleural effusion [ 9 , 13 – 15 ]. Similar findings were observed in our patients. Representative pre and post HCT CT images from representative patients in our study who developed PES are shown in Fig. 2 . The use of ruxolitinib prior to and during immediate post HCT period may have a favorable impact on PES. Use of ruxolitinib in peritransplant period has been shown to be safe and does not have adverse impact on engraftment [ 16 ]. Case reports have also described improvement in pulmonary EMH and respiratory parameters after ruxolitinib treatment which could be a useful intervention prior to alloHCT to improve respiratory function [ 17 – 19 ]. Both PAH and pulmonary EMH associated with MF have been shown to improve after successful alloHCT [ 11 , 14 ] In our study, occurrence of PES did not contribute to NRM and all patients could be managed by supportive measures and or corticosteroids. Although this diagnosis requires exclusion of infectious complications, awareness of this entity would allow for early initiation of corticosteroid therapy and thereby prevent respiratory compromise and associated morbidity in the immediate post HCT period. Recognizing this syndrome may also prevent patients from undergoing invasive procedures like biopsy and a trial of empiric steroids should be tried once infections have been ruled out by bronchioalveolar lavage. Given the association that we found between PAH and PES, patients should be closely observed for PES during the time of engraftment particularly if they have PAH prior to HCT. Declarations Conflicts of interest HA and MAM have received research support from Incyte. The remaining authors have no relevant conflicts of interest to declare. Author contributions VP developed study concept. SO and IA conducted the study and collected data. DS assisted in data collection. DY performed statistical analysis. SR analyzed imaging studies. VP, SO and IA wrote the initial draft of the manuscript. All authors provided intellectual input and contributed to revision of the initial manuscript. References Ali H, Pullarkat V, Snyder D. Biology and Current Treatment of Myeloproliferative Neoplasms. Cancer Treat Res. 2021;181:151–165. doi: 10.1007/978-3-030-78311-2_9 Choudhary D, Doval D, Khandelwal V, Setia R, Handoo A. Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study. Blood Cell Ther. 2023;6:5–10. Published 2023 Feb 10. doi: 10.31547/bct-2022-003 Acosta-Medina AA, Baranwal A, Johnson IM, et al. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023;29:360.e1-360.e8. doi:10.1016/j.jtct.2023.02.002 Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893–898. doi: 10.1038/sj.bmt.1703015 Nürnberger W, Willers R, Burdach S, Göbel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol. 1997;74:221–224. doi: 10.1007/s002770050288 Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant. 1996;18:177–184. Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469–475. doi: 10.1038/bmt.2014.296 Chang L, Frame D, Braun T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014;20:1407–1417. doi: 10.1016/j.bbmt.2014.05.022 Singh I, Mikita G, Green D, Risquez C, Sanders A. Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. Pulm Circ. 2017;7:261–267. Published 2017 Mar 10. doi: 10.1177/2045893217702064 Yang M, Covington MF, Nguyen BD, Johnson GB, Mesa RA, Roarke MC. 99m Tc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis. J Nucl Med Technol. 2018;46:368–372. doi: 10.2967/jnmt.118.210534 Gupta R, Jamal F, Yang D, et al. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant. 2020;55:877–883. doi: 10.1038/s41409-019-0741-8 Singh H, Kurman JS, Jani CT, Rao N, Benn BS. An 80-year-old woman with myelofibrosis and diffuse mosaic attenuation on chest computed tomography. Respir Med Case Rep. 2022;38:101705. Published 2022 Jul 11. doi: 10.1016/j.rmcr.2022.101705 Wyatt SH, Fishman EK. Diffuse pulmonary extramedullary hematopoiesis in a patient with myelofibrosis: CT findings. J Comput Assist Tomogr. 1994;18:815–817. doi: 10.1097/00004728-199409000-00023 Chunduri S, Gaitonde S, Ciurea SO, Hoffman R, Rondelli D. Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Haematologica. 2008;93:1593–1595. doi: 10.3324/haematol.13203 Enokida K, Tomomatsu K, Okada N, et al. Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis. Intern Med. 2021;60:449–452. doi: 10.2169/internalmedicine.4668-20 Ali H, Tsai NC, Synold T, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022;6:1444–1453. doi: 10.1182/bloodadvances.2021005035 Maccaferri M, Leonardi G, Marasca R, et al. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. Leuk Lymphoma. 2014;55:2207–2208. doi: 10.3109/10428194.2013.873538 Fujimoto A, Hamaguchi S, Suzuki R. Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib. Leuk Res Rep. 2022;17:100290. Published 2022 Feb 7. doi: 10.1016/j.lrr.2022.100290 Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;28:1486–1493. doi: 10.1038/leu.2014.5 Additional Declarations Yes Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3970614","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":273966054,"identity":"c35bf03b-c2df-4397-9deb-615c44788b0d","order_by":0,"name":"Vinod Pullarkat","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA00lEQVRIie3OrwrCUBTH8SODmzZWz0D0FTYuzLKHOSsmg2A1LC2J1q04X0EEMV4Y3OQDmHQW81aM4h02w/40kfstJ334HQCd7gdzb2IgCnUBDAGDqAu5EAiqCWPUm5huN+IkM1fQ8srtbFWV1QlGk82uhWRnReTCR2kdnPQMfHgp2lZMRRgFIK2jYcUQJiiaiY01eVEwluajBwlj8l1psg+xo2bCkM1FuCbuySl30hg5YrNQxNgX5ZO8bZ7fyyoORmi3PPadmkDqR1R9V3Q6ne7vewO6SEW7XrIYAQAAAABJRU5ErkJggg==","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":true,"prefix":"","firstName":"Vinod","middleName":"","lastName":"Pullarkat","suffix":""},{"id":273966055,"identity":"64ad4a69-1708-42f0-ab67-07228e8dd7a7","order_by":1,"name":"Salman Otoukesh","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Salman","middleName":"","lastName":"Otoukesh","suffix":""},{"id":273966056,"identity":"a2353f59-a8d2-4d6c-90f6-dd2440539bb8","order_by":2,"name":"Idoroenyi Amanam","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Idoroenyi","middleName":"","lastName":"Amanam","suffix":""},{"id":273966058,"identity":"b7f3d13c-d9e1-479f-b312-433fc0f7a586","order_by":3,"name":"Dongyun Yang","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Dongyun","middleName":"","lastName":"Yang","suffix":""},{"id":273966060,"identity":"c4e26382-9ba0-4b30-8056-ecc29bc53d99","order_by":4,"name":"Syed Rahmanuddin","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Syed","middleName":"","lastName":"Rahmanuddin","suffix":""},{"id":273966062,"identity":"2201ba8e-ca7c-4f8e-a3ef-2a53b6338f75","order_by":5,"name":"Diana Samuels","email":"","orcid":"","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Diana","middleName":"","lastName":"Samuels","suffix":""},{"id":273966064,"identity":"4bea0851-ab34-4791-b735-bbba1d2f0b91","order_by":6,"name":"Amandeep Salhotra","email":"","orcid":"https://orcid.org/0000-0002-9302-5041","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Amandeep","middleName":"","lastName":"Salhotra","suffix":""},{"id":273966065,"identity":"3d32231a-20ea-41af-ab44-abd8a75418da","order_by":7,"name":"Andrew Artz","email":"","orcid":"https://orcid.org/0000-0003-0803-9607","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Andrew","middleName":"","lastName":"Artz","suffix":""},{"id":273966067,"identity":"6dece9b8-945c-4755-9599-b03c466df101","order_by":8,"name":"Shukaib Arslan","email":"","orcid":"https://orcid.org/0000-0002-8447-9607","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Shukaib","middleName":"","lastName":"Arslan","suffix":""},{"id":273966068,"identity":"09a45e2d-c1fd-4d58-87a3-caeec4ef16ea","order_by":9,"name":"Ibrahim Aldoss","email":"","orcid":"https://orcid.org/0000-0001-9564-4498","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Ibrahim","middleName":"","lastName":"Aldoss","suffix":""},{"id":273966069,"identity":"b9afb654-826e-4eab-990e-29cb24b11c78","order_by":10,"name":"Karamjeet Sandhu","email":"","orcid":"https://orcid.org/0000-0001-8024-8484","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Karamjeet","middleName":"","lastName":"Sandhu","suffix":""},{"id":273966070,"identity":"2ae040ae-34b3-4bce-a0cd-0ad9b848f15a","order_by":11,"name":"Paul Koller","email":"","orcid":"https://orcid.org/0000-0003-3830-5320","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Paul","middleName":"","lastName":"Koller","suffix":""},{"id":273966071,"identity":"88cf7a74-6fbb-49c8-aba6-a563e65f9592","order_by":12,"name":"Ahmed Aribi","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Ahmed","middleName":"","lastName":"Aribi","suffix":""},{"id":273966072,"identity":"16ced48e-8dca-4244-b392-eaa9ec8748d0","order_by":13,"name":"Peter Curtin","email":"","orcid":"","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Peter","middleName":"","lastName":"Curtin","suffix":""},{"id":273966073,"identity":"dafd596c-534b-40da-8cb8-239cf4b8963f","order_by":14,"name":"Anthony Stein","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Anthony","middleName":"","lastName":"Stein","suffix":""},{"id":273966074,"identity":"11761dfc-4a64-4c73-9079-9ff44abff031","order_by":15,"name":"Guido Marcucci","email":"","orcid":"","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Guido","middleName":"","lastName":"Marcucci","suffix":""},{"id":273966075,"identity":"31b0690a-df14-46e6-ac17-35d5372961ad","order_by":16,"name":"Monzr Al Malki","email":"","orcid":"https://orcid.org/0000-0001-8226-471X","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Monzr","middleName":"Al","lastName":"Malki","suffix":""},{"id":273966076,"identity":"bb772bf0-b2e7-4593-b191-a3ab40df337b","order_by":17,"name":"Haris Ali","email":"","orcid":"https://orcid.org/0000-0002-9728-7292","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Haris","middleName":"","lastName":"Ali","suffix":""},{"id":273966077,"identity":"92e19ef6-d4bf-47fb-9517-b393255eff24","order_by":18,"name":"Ryotaro Nakamura","email":"","orcid":"https://orcid.org/0000-0002-9082-0680","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Ryotaro","middleName":"","lastName":"Nakamura","suffix":""}],"badges":[],"createdAt":"2024-02-19 18:00:40","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3970614/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3970614/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":51500534,"identity":"8b7c3852-19fb-4d72-ad2d-5d373e29107f","added_by":"auto","created_at":"2024-02-22 17:00:54","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1456641,"visible":true,"origin":"","legend":"\u003cp\u003eRepresentative CT images from 2 patients prior to HCT and during development of PES are shown. Loss of lung volume as well as g round glass opacities and areas of consolidation are evident.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-3970614/v1/9627cd030964f251373c0abc.png"},{"id":51500533,"identity":"871feb16-161e-428c-b3f2-e6696d6b0af2","added_by":"auto","created_at":"2024-02-22 17:00:54","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":316089,"visible":true,"origin":"","legend":"\u003cp\u003eThe overall survival (OS) and non-relapse mortality (NRM) of the whole cohort (Panels A ad B) and stratified by PES (Panels C and D) are shown.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-3970614/v1/ccbd63691b0a7dcc0bfe4dee.png"},{"id":53487487,"identity":"63f357e1-8145-4131-a443-5a8cbee1c1df","added_by":"auto","created_at":"2024-03-26 15:10:30","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":510988,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3970614/v1/5a3aab7f-760e-4db1-a9af-42a1f011c29c.pdf"}],"financialInterests":"\u003cb\u003eYes\u003c/b\u003e","formattedTitle":"Pulmonary Engraftment Syndrome: A unique complication of allogeneic hematopoietic cell transplantation for myelofibrosis","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAllogeneic hematopoietic cell transplantation (alloHCT) is the only potentially curative modality for primary and secondary myelofibrosis due to other myeloproliferative neoplasms (MPN).[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] Although alloHCT is associated with favorable long-term outcomes, there is high non-relapse mortality (NRM) post-transplant which could be as high as 35%.[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e] This relatively high NRM is likely contributed by advanced age, comorbid conditions, and organ dysfunction that frequently exists in these patients [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eEngraftment syndrome (ES) is a clinical syndrome that includes fever, skin rash, pulmonary infiltration, weight gain, liver and/or renal dysfunction, and/or rarely encephalopathy, which usually occurs at the time of neutrophil engraftment and carries the potential risk of multi-organ failure and/or death.[\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e] Although criteria for diagnosis of ES have been proposed, ES remains a diagnosis of exclusion, and its reported incidence varies widely. Since there are no standard diagnostic criteria for ES, this entity has a wide range of incidence (7\u0026ndash;90%) in literature. [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e] ES may have an adverse impact on HCT outcome. In a study of 927 pediatric patients who underwent alloHCT, Chang et al reported a significantly higher incidence of grade 2\u0026ndash;4 acute GVHD (75% vs. 34%), 2-year non-relapse mortality (38% vs. 19%), and lower overall survival (2-yr OS) (38% vs. 54%) compared with the non-ES group (P\u0026thinsp;\u0026lt;\u0026thinsp;0.001). [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] Differences in patient populations, HCT characteristics, and the nature of the disease may influence the incidence of ES. The pathophysiology of ES is not well understood, but inflammatory cytokines are implicated, leading to capillary leak, constitutional symptoms, and organ failure.[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eIn myelofibrosis patients undergoing alloHCT, we have observed a variant of engraftment syndrome manifesting as pulmonary infiltrates with or without hypoxemia which we termed pulmonary engraftment syndrome (PES). This presentation could be related to pulmonary extramedullary hematopoiesis that has been described in MF patients [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Therefore, we sought to characterize this unique syndrome further and determine its association with pre-HCT patient and disease characteristics and determine its impact on HCT outcome. We previously published our experience with pulmonary arterial hypertension (PAH) in myelofibrosis which was associated with adverse HCT outcomes [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Therefore we also sought to determine if an association exists between PES and pre-HCT pulmonary tests, particularly PAH.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003ePatients\u003c/h2\u003e \u003cp\u003e This study was approved by the Institutional Review Board of City of Hope Medical Center. From our HCT database, we identified 83 patients with primary/secondary myelofibrosis who underwent alloHCT at our institution from 2015 to 2020. Data on patient demographics, disease characteristics, disease status at HCT, mutations, HCT-related variables and outcome measures were collected from patient medical records.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eDefinition of pulmonary engraftment syndrome\u003c/h2\u003e \u003cp\u003eWe defined pulmonary ES was defined as the combination of new onset of pulmonary opacities in the absence of infection, fluid overload, or left ventricular dysfunction with or without hypoxemia occurring between ten to twenty days after stem cell infusion. All patients were required to have neutrophil engraftment after stem cell infusion. Other characteristics for engraftment syndrome were noted which included: noninfectious fever, erythematous rash not attributed to GvHD, liver dysfunction, acute kidney injury and encephalopathy.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eDescriptive statistics were used for patient baseline demographic, disease, and transplant characteristics. The associations between baseline characteristics and pulmonary ES were assessed by Fisher\u0026rsquo;s exact test in the univariate analysis, and exact logistic regression models in the multivariable model. The HCT outcomes by pulmonary ES were evaluated by Kaplan-Meier curves and log-rank tests for OS, by cumulative incidence curves and Gray\u0026rsquo;s test for NRM and engraftments. All tests were 2-sided at 0.05 significance level.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003ePatient demographics and baseline characteristics\u003c/h2\u003e \u003cp\u003eAmong the 83 patients included in this study, 49% had PMF, and 51% had MF secondary to another MPN. Their median age was 62 years (range 55\u0026ndash;68) and the majority of the patients were male (n\u0026thinsp;=\u0026thinsp;53,64%). The \u003cem\u003eJAK2\u003c/em\u003e V617F mutation was detected in 65% (n\u0026thinsp;=\u0026thinsp;54) of patients. Prior to an alloHCT, 61% (n\u0026thinsp;=\u0026thinsp;51) had received treatment with ruxolitinib. The median spleen size was 20 cm (range 16\u0026ndash;23 cm). \u0026gt; 90% of patients had\u0026thinsp;\u0026ge;\u0026thinsp;MF2 bone marrow fibrosis. Patient characteristics are shown in detail in \u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e.\u003c/p\u003e \u003cp\u003e \u003cb\u003eHematopoietic Cell Transplantation\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eThe median HCT CI score was 2 (range 0\u0026ndash;7). Graft source for alloHCT was matched unrelated donor (MUD) in 54%, followed by matched related donor (MRD) in 23%, mis-matched unrelated (MMUD) in 12%, and haplo-identical donor in 11%. Mobilized peripheral blood stem cells were used as a graft source in 97.6% of donors. Fludarabine-melphalan was the most common conditioning regimen used (83%). Tacrolimus/sirolimus GVHD prophylaxis was used in more than half of the patients (57.8%, n\u0026thinsp;=\u0026thinsp;48). The median CD34\u0026thinsp;+\u0026thinsp;and CD3 cells were infused at a median 6x10\u003csup\u003e6\u003c/sup\u003e cells/kg (range: 2.49\u0026ndash;12.96) and 2.21x10\u003csup\u003e6\u003c/sup\u003ecells/kg (range: 0.25\u0026ndash;4.90) respectively. The median time for neutrophil engraftment was 20.0 days. The median time for platelet engraftment was 37.0 days. Details of HCT are depicted in \u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv class=\"gridtable\"\u003e\n\u003cdiv class=\"colspec\" align=\"left\"\u003eTable\u0026nbsp;1. Patient and HCT characteristics\u0026nbsp;\u003c/div\u003e\n\u003ctable id=\"Taba\" style=\"width: 315.461px;\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eTotal (N\u0026thinsp;=\u0026thinsp;83)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eAge\u0026nbsp;at\u0026nbsp;HCT,\u0026nbsp;years\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMedian\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e62\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eInterquartile\u0026nbsp;range\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e55,\u0026nbsp;68\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eRange\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e(17\u0026ndash;75)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eRecipient\u0026nbsp;sex\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMale\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e53\u0026nbsp;(63.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFemale\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e30\u0026nbsp;(36.1%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eKarnofsky\u0026nbsp;performance\u0026nbsp;status\u0026nbsp;%\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMissing\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e3\u0026nbsp;(3.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e70\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e6\u0026nbsp;(7.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e80\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e31\u0026nbsp;(37.3%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e90\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e35\u0026nbsp;(42.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e100\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e8\u0026nbsp;(9.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e80\u0026ndash;100\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e74\u0026nbsp;(89.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u0026lt;80\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e6\u0026nbsp;(7.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eUnknown\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e3\u0026nbsp;(3.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eHCT\u0026nbsp;Comorbidity\u0026nbsp;Index\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMedian\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eInterquartile\u0026nbsp;range\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e0,\u0026nbsp;3\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eRange\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e(0\u0026ndash;7)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e0\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e21\u0026nbsp;(25.3%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e1\u0026ndash;2\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e24\u0026nbsp;(28.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u0026ge;\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e34\u0026nbsp;(41%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eUnknown\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e4\u0026nbsp;(4.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003ePrimary MF\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eYes\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e41\u0026nbsp;(49.4%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eNo\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e42\u0026nbsp;(50.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eJAK2 mutation\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eYes\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e54\u0026nbsp;(65.1%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eNo\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e29\u0026nbsp;(34.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eDegree\u0026nbsp;of\u0026nbsp;marrow fibrosis\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMissing\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2\u0026nbsp;(2.4%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e1+\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e6\u0026nbsp;(7.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2+\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e33\u0026nbsp;(39.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e3+\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e42\u0026nbsp;(50.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eRuxolitinib therapy\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eYes\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e50\u0026nbsp;(60.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eNo\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e33\u0026nbsp;(39.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003ePre\u0026nbsp;HCT\u0026nbsp;EF\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eN\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e81\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMedian\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e61\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eInterquartile\u0026nbsp;range\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e60,\u0026nbsp;65\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eRange\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e(45\u0026ndash;69)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003ePre\u0026nbsp;HCT\u0026nbsp;PASP\u0026nbsp;(mmhg)\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eN\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e79\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMedian\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e28\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eInterquartile\u0026nbsp;range\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e20,\u0026nbsp;34\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eRange\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e(3\u0026ndash;74)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003ePre\u0026nbsp;HCT\u0026nbsp;Spleen\u0026nbsp;Size\u0026nbsp;(cm)\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eN\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e75\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMedian\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e20\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eInterquartile\u0026nbsp;range\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e16,\u0026nbsp;23\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eRange\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e(10\u0026ndash;34)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eYear\u0026nbsp;of\u0026nbsp;HCT\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2015\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e17\u0026nbsp;(20.5%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2016\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e12\u0026nbsp;(14.5%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2017\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e14\u0026nbsp;(16.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2018\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e15\u0026nbsp;(18.1%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2019\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e21\u0026nbsp;(25.3%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2020\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e4\u0026nbsp;(4.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eDonor\u0026nbsp;Type\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMRD\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 78.4607px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e19\u0026nbsp;(22.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMUD\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 78.4607px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e45\u0026nbsp;(54.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMMUD\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 78.4607px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e10\u0026nbsp;(12%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eHaplo\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e9\u0026nbsp;(10.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eDonor\u0026nbsp;sex\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMale\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e60\u0026nbsp;(72.3%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFemale\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e23\u0026nbsp;(27.7%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eFemale\u0026nbsp;donor\u0026nbsp;to\u0026nbsp;male\u0026nbsp;recipient\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eYes\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e13\u0026nbsp;(15.7%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eNo\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e70\u0026nbsp;(84.3%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eDonor age\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMedian\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e36\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eInterquartile\u0026nbsp;range\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e27,\u0026nbsp;47\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eRange\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e(18\u0026ndash;69)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eGraft Source\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eBone\u0026nbsp;Marrow\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2\u0026nbsp;(2.4%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003ePeripheral\u0026nbsp;Blood Stem\u0026nbsp;Cells\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e81\u0026nbsp;(97.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eABO\u0026nbsp;blood\u0026nbsp;group\u0026nbsp;compatibility\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eABO\u0026nbsp;compatible\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e48\u0026nbsp;(57.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMinor\u0026nbsp;mismatch\u0026nbsp;(donor\u0026nbsp;is\u0026nbsp;O)\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e13\u0026nbsp;(15.7%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMajor\u0026nbsp;mismatch\u0026nbsp;(Recipient\u0026nbsp;is\u0026nbsp;O)\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e15\u0026nbsp;(18.1%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eBidirectional\u0026nbsp;(None\u0026nbsp;are\u0026nbsp;O)\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e7\u0026nbsp;(8.4%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eDonor/Recipient\u0026nbsp;CMV\u0026nbsp;serostatus\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eD-/R-\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e14\u0026nbsp;(16.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eD-/R+\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e29\u0026nbsp;(34.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eD+/R-\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e8\u0026nbsp;(9.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eD+/R+\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e32\u0026nbsp;(38.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eConditioning\u0026nbsp;regimen\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eBUSULFAN/CTX\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e4\u0026nbsp;(4.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFLUDARABINE/BUSULFAN\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e1\u0026nbsp;(1.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFLUDARABINE/CTX/TBI\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e1\u0026nbsp;(1.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFLUDARABINE/MELPHALAN\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e67\u0026nbsp;(80.7%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFLUDARABINE/MELPHALAN/Ruxolitinib/\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e2\u0026nbsp;(2.4%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFLUDARABINE/MELPHALAN/TBI\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e7\u0026nbsp;(8.4%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eFTBI/FLUDARABINE\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e1\u0026nbsp;(1.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eConditioning\u0026nbsp;Regimen\u0026nbsp;Intensity\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eMyeloblative\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e5\u0026nbsp;(6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eNon-myeloablative/Reduced\u0026nbsp;Intensity\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e78\u0026nbsp;(94%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e\u003cspan class=\"Bold\"\u003eGVHD\u0026nbsp;prophylaxis\u003c/span\u003e\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eCTX/TACROLIMUS/CELLCEPT\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e14\u0026nbsp;(16.9%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eTACROLIMUS/MTX\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e5\u0026nbsp;(6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eTACROLIMUS/MTX/BORTEZOMIB\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e1\u0026nbsp;(1.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eTACROLIMUS/SIROLIMUS\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e48\u0026nbsp;(57.8%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eTACROLIMUS/SIROLIMUS/MTX\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e3\u0026nbsp;(3.6%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eTACROLIMUS/SIROLIMUS/OTHER\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e1\u0026nbsp;(1.2%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 218px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003eTACROLIMUS/SIROLIMUS/Ruxolitinib\u003c/div\u003e\n\u003c/td\u003e\n\u003ctd style=\"width: 75px;\" align=\"left\"\u003e\n\u003cdiv class=\"SimplePara\"\u003e11\u0026nbsp;(13.3%)\u003c/div\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePulmonary Engraftment Syndrome\u003c/h2\u003e \u003cp\u003eTwenty-five patients (30%) had pulmonary infiltrates between days 10 and 20 of HCT. Radiologic findings included ground glass opacities, areas of consolidation or pulmonary nodules. Among them, eighteen patients (72%) met the criteria for pulmonary ES. Eight patients (44%) required an ICU admission. Fifteen (83%) patients had hypoxemia that required supplemental oxygen, and six (40%) of these patients required intubation with mechanical ventilation. Of the remaining patients with hypoxemia, two patients (13%) required high flow oxygen and seven (47%) required 2-6L of oxygen via nasal cannula. The most common engraftment symptoms included fever (33%), diarrhea (33%), and rash (22%). Half (n\u0026thinsp;=\u0026thinsp;9) of the patients with PES required systemic steroid therapy.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eRisk factors for pulmonary engraftment syndrome\u003c/h2\u003e \u003cp\u003eThe association of pre-HCT pulmonary parameters with PES is shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e2\u003c/span\u003e. Demographic factors and transplant characteristics did not reveal any risk factors for PES (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Pre-HCT CT scan chest was reported as normal in 87% of patients. Among the 18 patients who experienced PES, 9 had nodules (\u0026le;\u0026thinsp;5mm) on pre HCT CT imaging. Representative CT images for 2 patients with PES are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAssociation of disease and HCT factors with occurrence of PES\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c6\" namest=\"c3\"\u003e \u003cp\u003e\u003cem\u003ePES\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c9\" namest=\"c7\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eN\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eYes\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eNo\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e\u003cem\u003eFisher's exact test p value\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eAdjusted OR (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u003cem\u003eP value*\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge at HCT (years)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(20.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e35(79.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(23.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30(76.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.88(0.24,3.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(20.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e42(79.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(23.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e23(76.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.07(0.29,3.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eKPS, %\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e90\u0026ndash;100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(23.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(76.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(18.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30(81.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.86(0.23,3.04)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHCT Comorbidity Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(19.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e17(81.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026ndash;2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(28.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e18(72.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.67(0.28,11.02)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6(17.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28(82.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.98(0.19,5.71)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMatched\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13(20.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e51(79.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMMUD or Haplo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(26.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e14(73.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.28(0.28,5.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale to Male HCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16(22.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e54(77.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.71\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2(15.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11(84.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.53(0.05,3.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrimary MF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8(19.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(80.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(23.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e32(76.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.18(0.34,4.17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eJAK2 mutation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14(25.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e40(74.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.16\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(13.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e25(86.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.39(0.08,1.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDegree of fibrosis (MF grade)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026thinsp;+\u0026thinsp;or 2+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(23.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30(76.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(21.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(78.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.88(0.24,3.24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRuxolitinib use\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14(28.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e36(72.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.099\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(12.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e29(87.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.35(0.07,1.34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;EF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(27.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e29(72.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.77\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(17.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e34(82.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.74(0.20,2.70)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;BMT\u0026nbsp;PASP\u0026nbsp;(mmHg)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(9.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e39(90.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.011\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.011\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e12(33.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e24(66.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e4.78(1.26,22.69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(14.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e52(85.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.042\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.042\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(38.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11(61.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.68(1.13,12.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;Spleen\u0026nbsp;Size\u0026nbsp;(cm)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6(15.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(84.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.23\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(27.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e26(72.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.21(0.54,9.82)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;CT\u0026nbsp;chest\u0026nbsp;finding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17(23.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e55(76.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.42\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1(9.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10(90.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.29(0.01,2.52)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(17.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e52(82.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.25\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(33.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10(66.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.60(0.50,13.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1/FVC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13(21.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e47(78.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3(16.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15(83.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.84(0.08,5.40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT DLCO\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(23.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e16(76.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(19.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e45(80.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.79(0.18,4.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003e* Based on exact logistic regression adjusting for Pre HCT pulmonary pressure\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAssociation of patient and HCT characteristics with OS and NRM\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"13\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c13\" colnum=\"13\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"5\" nameend=\"c8\" namest=\"c4\"\u003e \u003cp\u003e\u003cem\u003eOverall Survival\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"5\" nameend=\"c13\" namest=\"c9\"\u003e \u003cp\u003e\u003cem\u003eNRM\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eN\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003e1 Yr (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eHR (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003eP*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cem\u003eAdjusted HR (95%CI)\u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eP\u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u003cem\u003e100 day (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e \u003cp\u003e\u003cem\u003eHR (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c11\"\u003e \u003cp\u003e\u003cem\u003eP*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u003cem\u003eAdjusted HR (95%CI) \u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c13\"\u003e \u003cp\u003e\u003cem\u003eP\u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge at HCT, years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.656(0.494,0.776)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.114(0.041,0.227)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.615(0.445,0.747)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.08(0.55,2.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.22(0.62,2.40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.205(0.095,0.344)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.13(0.51,2.51)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.19(0.53,2.66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.657(0.512,0.769)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.132(0.057,0.238)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.84\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.600(0.405,0.750)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.16(0.59,2.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.18(0.58,2.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.200(0.079,0.360)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.16(0.51,2.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.09(0.47,2.51)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eKPS, %\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e90\u0026ndash;100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.647(0.484,0.771)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.186(0.086,0.315)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.25\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.649(0.473,0.779)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.96(0.48,1.90)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.93(0.47,1.85)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.108(0.034,0.233)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.63(0.27,1.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.60(0.25,1.44)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHCT Comorbidity Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.571(0.338,0.749)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.238(0.083,0.437)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026ndash;2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.513(0.304,0.689)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.89(0.40,2.01)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.13(0.46,2.79)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.120(0.029,0.280)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.67(0.25,1.79)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.72(0.26,1.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.765(0.584,0.875)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.48(0.21,1.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.84(0.33,2.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.147(0.053,0.287)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.60(0.23,1.56)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.65(0.25,1.71)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMatched\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.686(0.556,0.784)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.065\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.022\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.125(0.058,0.219)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.27\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMMUD or Haplo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.474(0.244,0.673)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.92(0.94,3.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.41(1.13,5.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.263(0.092,0.474)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.66(0.68,4.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.66(0.68,4.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale to Male HCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.627(0.503,0.729)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.157(0.083,0.252)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.82\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.692(0.373,0.872)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.96(0.37,2.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.12(0.43,2.92)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.154(0.022,0.399)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.15(0.41,3.27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.13(0.40,3.20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrimary MF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.707(0.543,0.822)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.171(0.074,0.301)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.44\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.568(0.405,0.702)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.37(0.70,2.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.12(0.56,2.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.143(0.057,0.266)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.34(0.60,2.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.38(0.61,3.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eJAK2 mutation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.630(0.487,0.743)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.99\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.167(0.081,0.278)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.57\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.651(0.448,0.795)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.00(0.50,1.98)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.18(0.56,2.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.138(0.042,0.289)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.78(0.34,1.78)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.79(0.34,1.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDegree of marrow fibrosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026thinsp;+\u0026thinsp;or 2+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.615(0.445,0.747)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.205(0.095,0.344)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.687(0.522,0.805)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.72(0.36,1.43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.68(0.33,1.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.119(0.043,0.237)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.65(0.28,1.52)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.71(0.29,1.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRuxolitinib therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.640(0.491,0.756)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.160(0.074,0.275)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.64\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.632(0.442,0.772)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.10(0.56,2.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.32(0.63,2.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.152(0.054,0.295)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.21(0.55,2.66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.21(0.55,2.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;EF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.721(0.553,0.835)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.87\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.125(0.045,0.248)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.55\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.585(0.420,0.718)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.06(0.53,2.09)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.84(0.41,1.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.195(0.090,0.329)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.32(0.57,3.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.30(0.56,2.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT PASP(mmHg)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.674(0.513,0.793)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.140(0.056,0.261)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.83\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.636(0.457,0.770)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.28(0.64,2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.88(0.88,4.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.194(0.084,0.338)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.14(0.50,2.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.09(0.48,2.47)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.719(0.587,0.815)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.007\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt;\u0026thinsp;0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.115(0.050,0.209)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e\u003cb\u003e0.031\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e\u003cb\u003e0.040\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.444(0.216,0.651)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.58(1.24,5.40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4.68(1.93,11.37)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.333(0.131,0.552)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e2.55(1.07,6.08)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e2.42(1.04,5.62)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;Spleen\u0026nbsp;Size\u0026nbsp;(cm)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.872(0.719,0.945)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.103(0.032,0.222)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.083\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.094\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.444(0.280,0.596)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.70(1.67,8.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4.14(1.83,9.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.194(0.084,0.338)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e2.18(0.88,5.39)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e2.17(0.88,5.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT CT\u0026nbsp;chest\u0026nbsp;finding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.651(0.528,0.749)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.139(0.071,0.229)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.60\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.545(0.229,0.780)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.42(0.59,3.44)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.84(0.75,4.55)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.273(0.058,0.552)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.47(0.50,4.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.36(0.44,4.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.635(0.504,0.740)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.96\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.175(0.093,0.278)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.21\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.660(0.365,0.843)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.82(0.34,1.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.03(0.41,2.54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.067(0.004,0.270)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.38(0.09,1.60)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.39(0.09,1.68)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1/FVC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.631(0.496,0.740)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.150(0.073,0.252)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.97\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.667(0.404,0.834)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.72(0.30,1.73)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.88(0.35,2.27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.167(0.039,0.372)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.78(0.26,2.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.98(0.32,3.03)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT DLCO\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.714(0.472,0.860)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.064\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.048(0.003,0.202)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.39\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.624(0.484,0.736)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.68(0.69,4.08)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.36(0.95,5.87)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.196(0.104,0.310)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.66(0.58,4.73)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.59(0.55,4.58)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePES\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.677(0.549,0.776)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.062\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.074\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.138(0.068,0.234)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.26\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.500(0.259,0.701)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.94(0.95,3.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.93(0.94,3.97)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.222(0.065,0.436)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.65(0.70,3.89)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.63(0.70,3.83)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"13\"\u003e* based on univariate analysis, log-rank test for OS, and Gray\u0026rsquo;s test for NRM\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"13\"\u003e\u0026dagger; Based on multivariable Cox regression model for OS adjusting for donor type and pre BMT spleen size, and Fine and Gray regression model for NRM adjusting for donor type.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003ePulmonary hypertension is a well-recognized complication of MF. Pulmonary artery systolic pressure measurement was available in 79 patients. In this cohort, the median pulmonary artery systolic pressure (PASP) for the cohort was 28 mmHg (range 3\u0026ndash;74 mm Hg). Pulmonary artery hypertension (defined as PASP\u0026thinsp;\u0026ge;\u0026thinsp;35 mmHg) was observed in 61 patients (77%) in this cohort. PAH was associated with increased risk of PES with an odds ratio 3.68 (95% CI 1.13,12; \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.04)\u003c/p\u003e \u003cp\u003eAn abnormal pulmonary function test (PFT), defined as FEV1\u0026thinsp;\u0026lt;\u0026thinsp;80%, FEV1/FVC\u0026thinsp;\u0026lt;\u0026thinsp;70%, and DLCO\u0026thinsp;\u0026lt;\u0026thinsp;80 were found in 19%, 23% and 72% patients during pre-HCT testing, respectively. No association was seen between PFT abnormalities prior to transplant and the occurrence of PES was observed. (FEV1 p\u0026thinsp;=\u0026thinsp;0.25 [95% CI 2.60 0.50-13.32], FEV1/FVC p\u0026thinsp;=\u0026thinsp;1.00, [95% CI 0.84 0.08\u0026ndash;5.40], DLCO p\u0026thinsp;=\u0026thinsp;0.74 [95% CI 0.18\u0026ndash;4.10]).\u003c/p\u003e \u003cp\u003eSpleen size was not associated with the occurrence of PES (p\u0026thinsp;=\u0026thinsp;0.23, 95% CI 2.21 0.54\u0026ndash;9.82). Neutrophil engraftment was noted to be earlier in those with PES (median 17 days vs 20 days) but this was not statistically significant (p\u0026thinsp;=\u0026thinsp;0.20).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eOverall Survival (OS) and Non-Relapse Mortality (NRM)\u003c/h2\u003e \u003cp\u003eThe 12-month OS and 2-yr OS were 65% and 63%, respectively. The day 100 mortality was 16% and 2-year NRM was 24%. \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e Patients who experienced PES had no difference in overall survival (OS) and non-relapse mortality (NRM) in comparison to those who did not have PES (HR;1.93, 95% CI 0.94\u0026ndash;3.97, P 0.074 and HR 1.63; 95% CI 0.70\u0026ndash;3.83, P 0.26, respectively).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eMedian ICU stay for patients with PES was 18 days. Patients with median PASP\u0026thinsp;\u0026gt;\u0026thinsp;35 and pre-HCT spleen size\u0026thinsp;\u0026gt;\u0026thinsp;20 cm had worse OS in multivariate analysis (HR 2.58, 95% CI 1.24\u0026ndash;5.40, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001, and HR 4.14, 95% CI 1.83\u0026ndash;9.36, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), while pre-HCT median PASP of greater or equal with 35 mmHg was associate with worse NRM (HR 2.42, 95% CI 1.04\u0026ndash;5.62, p 0.040)\u003c/p\u003e \u003cp\u003ePatient, donor, and transplant characteristics and their association with OS and NRM are listed in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we describe a novel variant of engraftment syndrome consisting of predominantly pulmonary infiltrates, occurring around the time of neutrophil engraftment in patients undergoing alloHCT for MF. Only a third of these patients had extrapulmonary features of engraftment syndrome. Although this syndrome was not associated with decreased OS or increased NRM, it was associated with significant morbidity and requires early recognition to initiate corticosteroid therapy which appears to be effective.\u003c/p\u003e \u003cp\u003eAlthough the precise mechanism of PES remains unclear, it appears related to pulmonary extramedullary hematopoiesis (EMH) and PAH which are unique comorbidities in MF patients undergoing HCT. Cardiopulmonary morbidity frequently coexists in patients with myelofibrosis and PAH is a frequent occurrence in these patients. We have previously shown that PAH is common in MF patients and contributes to morbidity and mortality after alloHCT in MF [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. In that study PAH was present in up to 50% of the cases prior to transplant and was associated with inferior overall survival (OS) (58.9% vs. 88.8%, P\u0026thinsp;=\u0026thinsp;0.025) and increased NRM (21.6% vs. 7.1%, P\u0026thinsp;=\u0026thinsp;0.007).[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] In this cohort of patients, we further confirm the association of PAH with adverse HCT outcome and show an association of PES with PAH prior to HCT. Other contributing factors to cardiopulmonary comorbidity in MF may include the hemodynamic changes related to splenomegaly and portal hypertension as well as chronic thromboembolic phenomena.\u003c/p\u003e \u003cp\u003eVarious reports have documented pulmonary EMH in patients with myelofibrosis, both primary and secondary to another MPN. This has been demonstrated in both biopsy specimens as well as non-invasively using technetium sulfur colloid scintigraphy [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Pulmonary EMH has also been implicated in pathogenesis of PAH in MF and involvement of pulmonary arteries by EMH as well as arteriopathy has been demonstrated in biopsy specimens [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The contribution of pulmonary EMH to PAH may explain the association of PES with PAH that we observed in this study. It can be hypothesized that engraftment of donor cells in foci of pulmonary EMH may underlie the pathogenesis of PES. Routine chest CT imaging appears insensitive to demonstrate pulmonary EMH unless it is symptomatic. In our cohort of 18 patients who experienced PES only half had small nodules (less than 1 cm) detected on pre HCT chest CT imaging. Given the prognostic significance of pulmonary EMH to HCT outcome it may be useful to perform specialized imaging by magnetic resonance imaging, Indium \u003csup\u003e111\u003c/sup\u003e or sulfur colloid scintigraphy to determine extent of pulmonary EMH and assess pre HCT risk in patients with MF, particularly those with abnormal pre HCT chest imaging or PAH.\u003c/p\u003e \u003cp\u003eA variety of radiologic findings have been observed in patients with pulmonary EMH. These include ground glass opacities, areas of consolidation, pulmonary nodules as well as pleural effusion [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan additionalcitationids=\"CR14\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Similar findings were observed in our patients. Representative pre and post HCT CT images from representative patients in our study who developed PES are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003eThe use of ruxolitinib prior to and during immediate post HCT period may have a favorable impact on PES. Use of ruxolitinib in peritransplant period has been shown to be safe and does not have adverse impact on engraftment [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Case reports have also described improvement in pulmonary EMH and respiratory parameters after ruxolitinib treatment which could be a useful intervention prior to alloHCT to improve respiratory function [\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Both PAH and pulmonary EMH associated with MF have been shown to improve after successful alloHCT [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] In our study, occurrence of PES did not contribute to NRM and all patients could be managed by supportive measures and or corticosteroids. Although this diagnosis requires exclusion of infectious complications, awareness of this entity would allow for early initiation of corticosteroid therapy and thereby prevent respiratory compromise and associated morbidity in the immediate post HCT period. Recognizing this syndrome may also prevent patients from undergoing invasive procedures like biopsy and a trial of empiric steroids should be tried once infections have been ruled out by bronchioalveolar lavage. Given the association that we found between PAH and PES, patients should be closely observed for PES during the time of engraftment particularly if they have PAH prior to HCT.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eConflicts of interest\u003c/h2\u003e \u003cp\u003eHA and MAM have received research support from Incyte. The remaining authors have no relevant conflicts of interest to declare.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eAuthor contributions\u003c/h2\u003e \u003cp\u003eVP developed study concept. SO and IA conducted the study and collected data. DS assisted in data collection. DY performed statistical analysis. SR analyzed imaging studies. VP, SO and IA wrote the initial draft of the manuscript. All authors provided intellectual input and contributed to revision of the initial manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAli H, Pullarkat V, Snyder D. Biology and Current Treatment of Myeloproliferative Neoplasms. Cancer Treat Res. 2021;181:151\u0026ndash;165. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/978-3-030-78311-2_9\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eChoudhary D, Doval D, Khandelwal V, Setia R, Handoo A. Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study. Blood Cell Ther. 2023;6:5\u0026ndash;10. Published 2023 Feb 10. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.31547/bct-2022-003\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eAcosta-Medina AA, Baranwal A, Johnson IM, et al. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023;29:360.e1-360.e8. doi:10.1016/j.jtct.2023.02.002\u003c/li\u003e\n\u003cli\u003eSpitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893\u0026ndash;898. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/sj.bmt.1703015\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eN\u0026uuml;rnberger W, Willers R, Burdach S, G\u0026ouml;bel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol. 1997;74:221\u0026ndash;224. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s002770050288\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eCahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant. 1996;18:177\u0026ndash;184.\u003c/li\u003e\n\u003cli\u003eSpitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469\u0026ndash;475. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/bmt.2014.296\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eChang L, Frame D, Braun T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014;20:1407\u0026ndash;1417. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bbmt.2014.05.022\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eSingh I, Mikita G, Green D, Risquez C, Sanders A. Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. Pulm Circ. 2017;7:261\u0026ndash;267. Published 2017 Mar 10. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/2045893217702064\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eYang M, Covington MF, Nguyen BD, Johnson GB, Mesa RA, Roarke MC. \u003csup\u003e99m\u003c/sup\u003eTc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis. J Nucl Med Technol. 2018;46:368\u0026ndash;372. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2967/jnmt.118.210534\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eGupta R, Jamal F, Yang D, et al. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant. 2020;55:877\u0026ndash;883. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41409-019-0741-8\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eSingh H, Kurman JS, Jani CT, Rao N, Benn BS. An 80-year-old woman with myelofibrosis and diffuse mosaic attenuation on chest computed tomography. Respir Med Case Rep. 2022;38:101705. Published 2022 Jul 11. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.rmcr.2022.101705\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eWyatt SH, Fishman EK. Diffuse pulmonary extramedullary hematopoiesis in a patient with myelofibrosis: CT findings. J Comput Assist Tomogr. 1994;18:815\u0026ndash;817. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/00004728-199409000-00023\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eChunduri S, Gaitonde S, Ciurea SO, Hoffman R, Rondelli D. Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Haematologica. 2008;93:1593\u0026ndash;1595. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3324/haematol.13203\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eEnokida K, Tomomatsu K, Okada N, et al. Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis. Intern Med. 2021;60:449\u0026ndash;452. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2169/internalmedicine.4668-20\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eAli H, Tsai NC, Synold T, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022;6:1444\u0026ndash;1453. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1182/bloodadvances.2021005035\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eMaccaferri M, Leonardi G, Marasca R, et al. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. Leuk Lymphoma. 2014;55:2207\u0026ndash;2208. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3109/10428194.2013.873538\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eFujimoto A, Hamaguchi S, Suzuki R. Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib. Leuk Res Rep. 2022;17:100290. Published 2022 Feb 7. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.lrr.2022.100290\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eTabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;28:1486\u0026ndash;1493. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/leu.2014.5\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-3970614/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3970614/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAllogeneic hematopoietic cell transplantation (alloHCT) is the only potentially curative modality for primary and secondary myelofibrosis (MF) due to other myeloproliferative neoplasms. However, alloHCT in MF is complicated by cardiopulmonary comorbidities that frequently exist in these patients, which in turn translates into higher non relapse mortality (NRM). We describe a syndrome of pulmonary infiltration and respiratory compromise (pulmonary engraftment syndrome, PES) that occurred at time of engraftment in patients undergoing alloHCT for MF. Eighteen of 83 (22%) patients experienced PES as defined and radiologic findings included ground glass opacities, consolidation or pulmonary nodularity. Only a third of patients had other features of engraftment syndrome. Pulmonary arterial hypertension was associated with occurrence of PES (Odds ratio 3.68 [95% CI 1.13,12; P\u0026thinsp;=\u0026thinsp;0.04]). There was no association of PES with pre HCT pulmonary function testing or imaging. Hypoxemia occurred in 15 of 18 patients. Although 44% of the 18 patients who developed PES required intensive care and 40% required mechanical ventilation, all patients responded to supportive management and treatment with corticosteroids. Occurrence of PES did not adversely impact overall survival or NRM. PES is a distinct syndrome that occurs after alloHCT for MF and is associated with significant morbidity making its early recognition important.\u003c/p\u003e","manuscriptTitle":"Pulmonary Engraftment Syndrome: A unique complication of allogeneic hematopoietic cell transplantation for myelofibrosis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-02-22 17:00:49","doi":"10.21203/rs.3.rs-3970614/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4afc9c4a-8991-49de-b6e2-351410a8dd14","owner":[],"postedDate":"February 22nd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":28877142,"name":"Biological sciences/Cancer/Haematological cancer/Myeloproliferative disease"},{"id":28877143,"name":"Biological sciences/Cancer/Cancer therapy/Cancer immunotherapy"}],"tags":[],"updatedAt":"2024-03-26T15:02:23+00:00","versionOfRecord":[],"versionCreatedAt":"2024-02-22 17:00:49","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3970614","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3970614","identity":"rs-3970614","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}